Processing

Please wait...

Settings

Settings

1. WO2020018425 - ANTIBODY-DEPENDENT CELL-MEDIATED TOXICITY MEDIATED BY ALT-803 AND NEO-201

Publication Number WO/2020/018425
Publication Date 23.01.2020
International Application No. PCT/US2019/041811
International Filing Date 15.07.2019
IPC
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4164
1,3-Diazoles
4184
condensed with carbocyclic rings, e.g. benzimidazoles
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
69
Boron compounds
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
38
Albumins
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 31/4184 (2006.01)
A61K 31/69 (2006.01)
A61K 38/38 (2006.01)
A61K 39/00 (2006.01)
A61K 39/395 (2006.01)
CPC
A61K 2039/507
A61K 31/4184
A61K 31/69
A61K 38/38
A61K 39/00
A61K 39/39558
Applicants
  • NANTCELL, INC. [US/US]; 9920 Jefferson Boulevard Culver City, California 90232, US
Inventors
  • SOON-SHIONG, Patrick; US
  • LEE, John H.; US
  • FANTINI, Massimo; US
Agents
  • FESSENMAIER, Martin; US
Priority Data
62/698,45416.07.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTIBODY-DEPENDENT CELL-MEDIATED TOXICITY MEDIATED BY ALT-803 AND NEO-201
(FR) TOXICITÉ À MÉDIATION CELLULAIRE DÉPENDANT DES ANTICORPS MÉDIÉE PAR ALT-803 ET NÉO-201
Abstract
(EN)
Compositions, methods, and uses are contemplated in which immune competent cells are (pre)treated with an IL-15 superagonist molecule and in which such cells are administered with a neoantigen antibody (especially NEO-201). Such compositions exhibit superior ADCC activity of immune competent cells that can be used in the treatment of cancer.
(FR)
L'invention concerne des compositions, des méthodes et des utilisations dans lesquelles des cellules immunocompétentes sont (pré)traitées avec une molécule super-agoniste d'IL-15 et dans lesquelles de telles cellules sont administrées avec un anticorps néoantigène (en particulier NEO-201). De telles compositions présentent une activité ADCC supérieure de cellules immunocompétentes qui peuvent être utilisées dans le traitement du cancer.
Latest bibliographic data on file with the International Bureau